Certara (CERT) Completes Acquisition of Chemaxon
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Certara Completes Acquisition of Chemaxon
October 2, 2024 4:15 PM EDTThe combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization.
RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has completed the acquisition of Chemaxon.
Chemaxon develops leading scientific informatics software products used by the life sciences industry for in-silico research. Certara develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties of large and small molecules.
"Combining Chemaxons expertise with Certaras... More
